Você procurou por: nocturnal (Inglês - Maltês)

nocturnal
matul il-lejl

nocturnal confirmed2
bil-lejl ikkonfermata2

nocturnal confirmed 3
ikkonfermata bil-lejl 3

paroxysmal nocturnal haemoglobinuria
emoglobinurija notturna parossimali

paroxysmal nocturnal haemoglobinuria (pnh).
emoglobinurja notturna parossimali (pnh).

in paroxysmal nocturnal haemoglobinuria (pnh):
f’emoglobinurja notturna parossimali (pnh):

elevate bedhead (if you suffer from nocturnal symptoms)
tella’ l-bedhead (jekk tbati minn sintomi ta’ bil-lejl)

nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m.
ipogliċemija ta' matul il-lejl ikkonfermata kienet definita bħala episodji bejn nofsillejl u s-6 a.m b episodji minn ġimgħa 16

ryzodeg causes a lower rate of overall and nocturnal hypoglycaemia (table 2).
ryzodeg jikkawża rata iktar baxxa ta’ ipogliċemija ta’ matul il-lejl u ipogliċemija totali (tabella 2).

in some studies, reduction of nocturnal hypoglycaemia was associated with increased episodes of daytime hypoglycaemia.
f' xi studji, it - tnaqqis ta 'zokkor baxx fid- demm ta' matul il- lejl kien assoċjat ma 'żieda fl- episodji ta' zokkor baxx fid- demm matul il- ġurnata.

due to more sustained basal insulin supply with lantus, less nocturnal but more early morning hypoglycaemia can be expected.
peress li lantus jipprovdi livell sostnut tal-bżonn bażiku ta’ l-insulina, huwa mistenni li jkun hemm anqas possibbiltà ta’ ipogliċemija matul il-lejl iżda aktar filgħodu kmieni.

correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs.
b’mod simili, l-inċidenza ta’ ipogliċemija ta’ matul il-lejl kienet ta’ 32% fil-grupp ta’ insulin glargine / lispro vs.

clinical trials in patients with type 1 diabetes have demonstrated a reduced risk of nocturnal hypoglycaemia with insulin aspart compared with soluble human insulin.
studji kliniċi f’pazjenti bid-dijabete tat-tip 1 urew li hemm inqas riskju ta’ ipogliċemija mal-lejl bl- insulina aspart meta mqabbel ma’ insulina umana solubbli.

soliris (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh).
soliris (eculizumab) huwa indikat għat- trattament ta 'pazjenti b' emoglobinurja notturnali parossimali (pnh).

nasal congestion, pharyngolaryngeal pain, tachypnoea, bronchospasm, cough, dyspnoea paroxysmal nocturnal, hypoxia, rales, wheezing
konġestjoni nasali, uġigħ farinġolarinġeali, takipnea, bronkospasmi, sogħla, dispnea parossimali notturnali, ipoksja, ħsejjes tal-pulmun, tħarħir

soliris is used for the treatment of patients with a certain type of disease affecting the blood system called paroxysmal nocturnal haemoglobinuria (pnh).
soliris jintuża għall- kura ta ’ pazjenti b’ ċertu tip ta ’ marda li taffettwa s- sistema tad- demm imsejħa emoglobinurja notturna parossimali (pnh).

glycaemic control (hba1c) with levemir was comparable to nph insulin, with a lower risk of nocturnal hypoglycaemia and no associated weight gain.
il- kontroll gliċemiku (hba1c) b’levemir kien komparabbli ma’ insulina nph, b’riskju inqas ta’ ipogliċemija ta’ matul il-lejl u l-ebda żjieda assoċjata fil-piż.

if normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.
jekk ikun hemm livelli normali jew imnaqqsa ta’emoglobina glikata , il-possibbiltà t’attakki ta’ ipogliċemja rikurrenti, u dawk fejn il-pazjent ma jintebaħx bihom (speċjalment matul il-lejl), trid tkun ikkunsidrata.

correspondingly, the incidences of nocturnal hypoglycaemia were 32% in the insulin glargine / lispro group versus 52% in the nph / regular group.
b’mod simili, l-inċidenza ta’ ipogliċemija ta’ matul il-lejl kienet ta’ 32% fil- grupp ta’ insulin glargine/ lispro kontra 52% fil-grupp ta’ nph/ normali.

for fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.
fil-każ ta’ insulini li jaġixxu malajr, kull pazjent li qiegħed ukoll fuq insulina bażilari irid isib l-aħjar doża possibbli għaż- żewġ insulini biex il-livelli tal-glukożju jiġu kkontrollati matul il-gurnata kollha, speċjalment il- kontroll ta’ glukożju billejl/wara s-sawm.